Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expression.

Neoplasia (New York, N.Y.) - 1 Mar 2012

Derer Stefanie, Berger Sven, Schlaeth Martin, Schneider-Merck Tanja, Klausz Katja, Lohse Stefan, Overdijk Marije B, Dechant Michael, Kellner Christian, Nagelmeier Iris, Scheel Andreas H, Lammerts van Bueren Jeroen J, van de Winkel Jan G J, Parren Paul W H I, Peipp Matthias, Valerius Thomas

Abstract excerpt

Oncogenic KRAS mutations in colorectal cancer (CRC) are associated with lack of benefit from epidermal growth factor receptor (EGFR)-directed antibody (Ab) therapy. However, the mechanisms by which constitutively activated KRAS (KRAS(G12V)) impairs effector mechanisms of EGFR-Abs are incompletely...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antibody-Dependent Cell Cytotoxicity

Share to CCAAT-Enhancer-Binding Protein-beta

Share to Cetuximab

Share to Epidermal Growth Factor

Share to Mitogen-Activated Protein Kinases

Share to ras Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 22496619
DOI: 10.1593/neo.111636
PMCID: PMC3323897

Genes

EGFR
KRAS
EBP

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-22496619-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expression.PMID 22496619Read ↗

Fc-engineered EGF-R antibodies mediate improved antibody-dependent cellular cytotoxicity (ADCC) against KRAS-mutated tumor cells.Semantic proximity Read ↗

KRAS mutation confers resistance to antibody-dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells.Semantic proximity Read ↗

Cetuximab-mediated ADCC activity is correlated with the cell surface expression level of EGFR but not with the KRAS/BRAF mutational status in colorectal cancer.Semantic proximity Read ↗

Cetuximab inhibits gastric cancer growth in vivo, independent of KRAS status.Semantic proximity Read ↗

IκBα kinase inhibitor BAY 11-7082 promotes anti-tumor effect in RAS-driven cancers.Semantic proximity Read ↗

Identification of tumorigenic cells in Kras(G12D)-induced lung adenocarcinoma.Semantic proximity Read ↗

KRAS mutation in intrahepatic cholangiocarcinoma: Linkage with metastasis-free survival and reduced E-cadherin expression.Semantic proximity Read ↗

Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.Semantic proximity Read ↗

Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.